Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Acute LVO Stroke (GALLOP2)
NCT06788626Phase 3Not yet recruiting
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in ischemic stroke (2 arms). Primary endpoint: Ordinal shift of modified Rankin Scale at 90 days. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06788626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788626.